Australian Healthcare: Healthcare Daily: News, research & industry feedback

研报英文原文证据摘录

Australian Healthcare: Healthcare Daily: News, research & industry feedback

Global Research

17 July 2026ab

Australian Healthcare Equities

AustraliaHealthcare Daily: News, research & industry

feedback Healthcare

David Low

Analyst

david.low@ubs.com

Stocks covered: CSL, REG, TLX +61-2-9324 2843

James Meares

Competitor results Analyst

james.meares@ubs.com

+61-29-324 3575CSL - Swedish Orphan Biovitrum 2Q 2026 Results (16 July)

Grace Allen

Associate Analyst

SOBI's haemophilia franchise includes products co-owned with Sanofi. Key points from

grace-za.allen@ubs.com

the result with read across to CSL included: +61-2-9324 2000

Haemophilia B sales flat for the half. Alprolix SEK 1.1b (~US$115m)

Haemophilia A sales up 33%. The strong growth was driven by uptake of the

group’s newer therapy Altuvoct with Elcota sales down 30%.

UBS view: The steady Alprolix result (reflects European sales) is encouraging noting we

have assumed CSL’s global Idelvion sales drop by ~15% over the same period. Both

therapies are facing pressure from newer subcutaneous haemophilia B therapies.

News and press releases

REG - "Labor’s reforms harm the people they’re supposed to help: aged care

watchdog" (SMH, 16-Jul)

REG - "Inspector-General warns aged care reforms are driving older Australians into

crisis" (Inside Ageing, 16-Jul)

The outgoing Aged Care watchdog has issued a series of comments regarding the Aged

Care system. Key viewpoints from the Inspector-General Natalie Siegel-Brown include:

Calls for a rethink of the new user co-payment model in home care. She

argues user co-payments, long wait times and system complexity for home care

packages were undermining the government’s reforms.

Residential aged care costs the government an average $123k per person

each year, compared to $30k for home care.